483
Max Health, Subsero HealthMax Health, Subsero Health – FDA 483, Mar 4, 2022
Record Details
Max Health, Subsero Health in Sarasota, FL, was cited for failing to submit an Investigational New Drug (IND) application to the FDA. The firm conducted a randomized, double-blinded, placebo-controlled outpatient clinical trial for COVID-19 without the required IND. This represents a significant regulatory non-compliance in the conduct of clinical investigations.
View Company Profile
ID · 3b17b944-9d93-4525-b97f-819229496fb4
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.